Rec'd PCT/PTO 31 AUG 2005 10/506630 PATE

Docket No. 300622004601

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No.: EV 391 878 142 US

Date of Deposit: August 31, 2005

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail PostOffice to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Marian L. Christopher

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Rajesh S. GOKHALE et al.

Application No.: 10/506,630

Int'l. Filing Date: March 4, 2003

For: METHODS TO MEDIATE POLYKETIDE

SYNTHASE MODULE EFFECTIVENESS

Confirmation No. 1769

Examiner: Not yet assigned

Group Art Unit: Not yet assigned

RESPONSE TO NOTIFICATION OF DEFECTIVE RESPONSE

MAIL STOP PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Madam:

This is in response to the Notification of Defective Response (copy enclosed), mailed August 24, 2005, for which a response is due by September 24, 2005. Accordingly, this response is timely filed.

Please enter the following substitute Sequence Listing and remarks.

In the Sequence Listing:

Please insert a substitute paper copy of the Sequence Listing as new pages 1-25 after the Abstract in the above-mentioned application. A substitute computer readable form copy (CRF copy) of the Sequence Listing accompanies this response.

REMARKS

The Sequence Listing has been amended to correct the errors identified in the raw sequence listing error report mailed July 28, 2005. The undersigned hereby states that the substitute computer readable form copy (CRF copy) of the Sequence Listing and the substitute paper copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.825(a) and (b), respectively, are the same and contain no new matter. Accordingly, entry of the substitute Sequence Listing into the above-captioned case is respectfully requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to <u>Deposit Account No. 03-1952</u> referencing docket no. <u>300622004601</u>. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Date: August 2005

Kate H Murashiga

Registration No. 29,959

Morrison & Foerster LLP 3811 Valley Centre Drive

Suite 500

San Diego, California 92130-2332

Telephone: (858) 720-5112 Facsimile: (858) 720-5125

U. S. Patent and Trad no persons are required to respond to a collection of infor-

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, AirBill No. EV 391 878 142 US, in an envelope addressed to: MS PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below. Lista Dated: August 31, 2005 Signature: Marian Christopher ATTORNEY'S DOCKET NUMBER TRANSMITTAL LETTER TO THE UNITED STATES 300622004601 **DESIGNATED/ELECTED OFFICE (DO/EO/US)** U.S. APPLICATION NO. (If known, see 37 CFR 1.5) **CONCERNING A SUBMISSION UNDER 35 U.S.C. 371** 10/506,630 INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/US03/06910 4 March 2003 4 March 2002 TITLE OF INVENTION METHODS TO MEDIATE POLYKETIDE SYNTHASE MODULE EFFECTIVENESS APPLICANT(S) FOR DO/EO/US Rajesh S. GOKHALE et al. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. 2 х This is an express request to begin national examination procedures (35 U.S.C. 371 (f)). The submission must 3. include items (5), (6), (9) and (21) indicated below. 4. The US has been elected (Article 31). A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) is attached hereto (required only if not communicated by the International Bureau). a. has been communicated by the International Bureau. h is not required, as the application was filed in the United States Receiving Office (RO/US). C. An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)). is attached hereto. a. b. has been previously submitted under 35 U.S.C. 154(d)(4). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) a. are attached hereto (required only if not communicated by the International Bureau). have been communicated by the International Bureau. b have not been made; however, the time limit for making such amendments has NOT expired. C. have not been made and will not be made. d 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). 9 An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). (7 pgs) An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)). Items 11 to 20 below concern document(s) or information included: An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 11 An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 12 13. A preliminary amendment. (3 pgs) An Application Data Sheet under 37 CFR 1.76. 14 A substitute specification. 15. A power of attorney and/or change of address letter. 16 A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825 17. x (1 disk). A second copy of the published International Application under 35 U.S.C. 154(d)(4). 18 A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 19. Response to Notification of Defective Response (3 pages); Statement to Support Filing and Submission in Accordance with 37 C.F.R. 1.821-1.825 (2 pages); Paper Copy of Sequence 20. Other items or information: Listing (25 pages); Copy of Notification of Defective Response (10 pages); Return Receipt Postcard

PTO-1390 (Rev. 02-2005)

Approved for use through 03/31/2007. OMB 0651-0021
U. S. Patent and Trader fice; U.S. DEPARTMENT OF COMMERCE

5, no persons are required to respond to a collection of inform less it displays a valid OMB control number. Under the Paperwork Reduction A INTERNATIONAL APPLICATION NO. ATTORNEY'S DOCKET NUMBER U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 10/506,630 PCT/US03/06910 300622004601 PTO USE ONLY **CALCULATIONS** The following fees have been submitted 21. Basic national fee\$300 Examination fee If International preliminary examination report prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4)\$100 All other situations Search fee Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the TOTAL OF 21, 22 and 23 = 0.00 Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof. Number of each additional 50 or fraction **Total Sheets** Extra sheets thereof (round up to a whole number × \$250.00 /50 = -100 =Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months 0.00 from the earliest claimed priority date (37 CFR 1.492 (e)). NUMBER FILED | NUMBER EXTRA CLAIMS RATE Total claims - 20 = -3 = Independent claims MULTIPLE DEPENDENT CLAIM(s) (if applicable) TOTAL OF ABOVE CALCULATIONS = 0.00 Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by 1/2. 0.00 SUBTOTAL = 0.00 Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492 (f)). 0.00 **TOTAL NATIONAL FEE =** Fee for recording the enclosed assignment (37 CFR 1.21 (h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property 0.00 4-Month Extension Fee (see enclosed Petition for Extension of Time) TOTAL FEES ENCLOSED = 0.00 Amount to be refunded: Amount to be \$ charged: A check in the amount of \$ to cover the above fees is enclosed. b. 03-1952 in the amount of \$ 0.00 Please charge my Deposit Account No. to cover the above fees. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 03-1952 . A duplicate copy of this sheet is enclosed. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the International Application to pending status. SEND ALL CORRESPONDENCE TO: Kate H. Murashige **MORRISON & FOERSTER LLP** Kate H. Murashige 3811 Valley Centre Drive NAME Suite 500 San Diego, California 92130-2332 29,959 (858) 720-5112 REGISTRATION NUMBER **CUSTOMER NUMBER: 25225**

AUG 29 2005





UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address COMMISSIONER FOR PATENTS
PO. Box 1450
Alexandra, Viginia 27313-1450
www.uspto.gov.

U.S. APPLICATION NUMBER NO. FIRST NAMED APPLICANT ATTY. DOCKET NO. 10/506,630 Rajesh S Gokhale 300622004601

INTERNATIONAL APPLICATION NO.

PCT/US03/06910

LA. FILING DATE PRIORITY DATE

03/04/2003

03/04/2002

25225 MORRISON & FOERSTER LLP 3811 VALLEY CENTRE DRIVE SUITE 500 SAN DIEGO, CA 92130-2332

CONFIRMATION NO. 1769 371 FORMALITIES LETTER OC000000016848872*

Date Mailed: 08/24/2005

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495)

- Indication of Small Entity Status
- **Priority Document**
- Copy of the International Application filed on 09/03/2004
- Copy of the International Search Report filed on 09/03/2004
- Preliminary Amendments filed on 04/01/2005
- Information Disclosure Statements filed on 12/16/2004
- Biochemical Sequence Diskette filed on 04/01/2005
- Oath or Declaration filed on 04/01/2005
- Biochemical Sequence Listing filed on 04/01/2005
- Small Entity Statement filed on 09/03/2004
- U.S. Basic National Fees filed on 09/03/2004
- Priority Documents filed on 04/01/2005
- Power of Attorney filed on 04/01/2005

Applicant's response filed 04/01/2005 is hereby acknowledged. The following requirements set forth in the NOTIFICATION of MISSING REQUIREMENTS mailed 10/07/2004 have not been completed.

 A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).





For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

WINSTON M ALVARADO

Telephone: (703) 308-9140 EXT 206

PART 1 - ATTORNEY/APPLICANT COPY

		_
U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY, DOCKET NO.
10/506,630	PCT/US03/06910	300622004601

FORM PCT/DO/EO/916 (371 Formalities Notice)

RECEIVED





MORRISON & FOEDSTER United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS FO. Box 1450 Alexandra, Vaginia 22313-1450 www.uspio.gov

U.S. APPLICATION NUMBER NO.

FIRST NAMED APPLICANT

ATTY. DOCKET NO.

10/506,630

MORRISON & FOERSTER LLP

3811 VALLEY CENTRE DRIVE

SAN DIEGO, CA 92130-2332

SUITE 500

Rajesh S Gokhale

300622004601

INTERNATIONAL APPLICATION NO.

PCT/US03/06910

I.A. FILING DATE

PRIORITY DATE

03/04/2003

03/04/2002

CONFIRMATION NO. 1769 371 WITHDRAWAL NOTICE

OC000000016846290

Date Mailed: 08/24/2005

WITHDRAWAL OF PREVIOUSLY SENT NOTICE

The Acceptance Notice mailed on 07/28/2005 was sent in error and is hereby withdrawn. A corrected Notice is enclosed. The time period for reply runs from the mail date of the enclosed Notice. We apologize for any inconvenience this caused.

DOCKETED:

DUE DATE:

FINAL DUE DATE

WINSTON M ALVARADO

Telephone: (703) 308-9140 EXT 206

PART 1 - ATTORNEY/APPLICANT COPY

STIC Biotechnology Systems Branch

RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number:	/0/506,630
Source:	PUTIO
Date Processed by STIC:	4/21/05
•	

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE <u>CHECKER</u> <u>VERSION 4.2.2 PROGRAM</u>, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom. Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

- 1. EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm>, EFS Submission User Manual ePAVE)
- 2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
- Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 01/14/05):
 U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulany Street, Alexandria, VA 22314

Revised 01/24/05

Mase mail her notice with the prissur part.

Mathem Altereds
Residenced Stage Processing
Personal Security

Raw Sequence Listing Error Summary

RROR DETECTED	SUGGESTED CORRECTION	SERIAL NUMBER: 10/506, 6) 0	47
TTN: NEW RULES CASES:	PLEASE DISREGARD ENGLISH "AL	PHA" HEADERS, WHICH WERE INSERTED BY PTO S	OFTWARE
!Wrapped Nucleics Wrapped Aminos	The number/text at the end of each line was retrieved in a word processor after prevent "wrapping."	ne "wrapped" down to the next line. This may occur if yo er creating it. Please adjust your right margin to .3; this w	ur file vill
2Invalid Line Length	The rules require that a line not exceed	ed 72 characters in length. This includes white spaces.	
Misaligned Amino Numbering	The numbering under each 5th amino use space characters, instead.	acid is misaligned. Do not use tab codes between number	:rs;
4Non-ASCII	The submitted file was not saved in a ensure your subsequent submission	ASCII(DOS) text, as required by the Sequence Rules. Placed in ASCII text.	ease
5Variable Length	each n or Yaa can only represent a	s representing more than one residue. Per Sequence Rule single residue. Please present the maximum number of dicate in the <220>-<223> section that some may be miss	each
6Patentin 2.0 "bug"	sequences(s) Normal	caused the <220>-<223> section to be missing from amine ly, Patentln would automatically generate this section from the properties of the manually copy the relevant <220>-<223> sections applies to the mandatory <220>-<223> sections	m the tion to
7Skipped Sequences (OLD RULES)	(2) INFORMATION FOR SEQ ID 1	tional, please insert the following lines for each skipped s NO:X: (insert SEQ ID NO where "X" is shown) ERISTICS: (Do not insert any subheadings under this hea EQ ID NO:X: (insert SEQ ID NO where "X" is shown) ed	
	Please also adjust the "(ii) NUMBEI	R OF SEQUENCES:" response to include the skipped se	quences.
8 Skipped Sequences (NEW RULES)	Sequence(s) missing. If into <210> sequence id number <400> sequence id number 000	entional, please insert the following lines for each skipped	d sequence.
9Use of n's or Xaa's (NEW RULES)	Des 1 922 of Sequence Rules use of	letected in the Sequence Listing. 1<220>-<223> is MANDATORY if n's or Xaa's are presexplain location of n or Xaa, and which residue n or Xaa re	ent. represents.
10Invalid <213> Response	Per 1.823 of Sequence Rules, the or scientific name (Genus/species). <2 is Artificial Sequence	nly valid <213> responses are: Unknown, Artificial Sequence 220>-<223> section is required when <213> response is the section when <213> re	ince, or Unknown or
Use of <220>	Use of <220> to <223> is MANDA	<220> "Feature" and associated numeric identifiers and real TORY if <213> "Organism" response is "Artificial Sequence of genetic material in <220> to <223> section. 8, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence of Security Section)	ence" or
12Patentin 2.0 "bug"	Please do not use "Copy to Disk" for	unction of PatentIn version 2.0. This causes a corrupted fineric identifiers and responses (as indicated on raw sequer fanager" or any other manual means to copy file to floppy	ile,
13 Misuse of n/Xaa	"n" can only represent a single nuc	leotide; "Xaa" can only represent a single amino acid	
_			

AMC - Biotechnology Systems Branch - 09/09/2003



PCT

```
RAW SEQUENCE LISTING
                                                                                                                                                            DATE: 04/21/2005
                                                      PATENT APPLICATION: US/10/506,630
                                                                                                                                                           TIME: 09:58:27
                                                      Input Set : A:\30062-20046.01 - Seqlist (from parent .45).txt
                                                     Output Set: N:\CRF4\04212005\J506630.raw
               4 <110> APPLICANT: GOKHALE, Rajesh
                                   TSUJI, Stuart
               6
                                   KHOSLA, Chaitan
               7
                                   WU, Nicholas
                                   CANE, David
            10 <120> TITLE OF INVENTION: METHODS TO MEDIATE POLYKETIDE SYNTHASE
                                   MODULE EFFECTIVENESS
            13 <130> FILE REFERENCE: 300622004601
            15 <140> CURRENT APPLICATION NUMBER: US 10/506,630
C--> 16 <141> CURRENT FILING DATE: 2004-09-03
            18 <150> PRIOR APPLICATION NUMBER: PCT/US03/06910
            19 <151> PRIOR FILING DATE: 2002-03-04
            21 <150> PRIOR APPLICATION NUMBER: US 10/091,244
                                                                                                                                                                             9098 Not Comply
            22 <151> PRIOR FILING DATE: 2002-03-04
                                                                                                                                                                    Conscied Diskette Neede
            24 <150> PRIOR APPLICATION NUMBER: 60/361,758
            25 <151> PRIOR FILING DATE: 2002-03-04
            27 <160> NUMBER OF SEQ ID NOS: 41
            29 <170> SOFTWARE: FastSEQ for Windows Version 4.0
ERRORED SEQUENCES
            55 <210> SEQ ID NO: 3
            56 <211> LENGTH: 31
                                                                                                                                                     que source of gesetie noteriel
(see item//on
            57 <212> TYPE: PRT
            58 <213> ORGANISM: Artificial Sequence
            60 <220> FEATURE:
           Ser Glu Lys Val Ala Glu Tyr Leu Arg Arg Ala Thr Leu

65 1 5 10 15

66 Asp Leu Arg Ala Ala Arg Gln Arg Ile Arg Glu Leu Glu Ser Asp

67 20 25 30 miralined and acd

238 <210> SEQ ID NO: 18

239 <211> LENGTH: 18

240 <212> TYPE: PRT

241 <213> ORGANISM: Artificial Sequence

243 <220> FEATURE:

244 <223> OTHER INFORMATION: Intra-polypeptide linker

246 <400> SEQUENCE: 18

247 Gly Gly Ala Thr Gly Ala Company Arg Ala Thr Leu

Evan Junnary

Steet Junnary

(see item 3 on Evan Junnary

Steet Junnary

Steet
            61 <223> OTHER INFORMATION: (N-terminal linker of (M3)
E--> 65 1 (5)
E--> 67
            247 Gly Gly Ala Thr Gly Ala Glu Gln Ala Ala Pro Ala Thr Thr Ala Pro
```

misaligned hos.

E--> 248 1 (5

249 Val Asp

RAW SENCE LISTING

PATENT APPLICATION: US/10/506,630

E: 04/21/2005 TIME: 09:58:27

Input Set : A:\30062-20046.01 - Seqlist (from parent .45).txt

Output Set: N:\CRF4\04212005\J506630.raw

1369 <210> SEQ ID NO: 41 1370 <211> LENGTH: 1099 1371 <212> TYPE: PRT 1372 <213> ORGANISM: Artificial Sequence 1374 <220> FEATURE: 1375 <223> OTHER INFORMATION: Alignment of the EryA SU 1377 <400> SEQUENCE: 41 1378 Lys Asp Ala Asp Asp Ile Ile Gly Met Ala Phe Gly Val His Asn Gly 1379 1 1380 Glu Leu Glu Phe Ile Val Gly Arg Gly Asp Ala Val Thr Glu Met Thr 20 1382 Asp Leu Asp Ala Leu Phe Asp Pro Asp Pro Gln Arg His Gly Thr Ser 40 1384 Tyr Ser Arg His Ala Phe Leu Asp Gly Ala Asp Ala Ala Ile Ser Leu 50 1386 Met Gln Val Thr Thr Leu Phe Asn Ile Asp His Ser Arg Gly Ser Asp 1387 65 70 1388 Leu Ala Ala Tyr Gln Gly Gln Asp Ala Val Val Pro Glu Asp Ser 1390 Glu Leu Leu Thr Asn Ser Ser Ala Val Val Ala Val Leu Leu Ala Val 105 100 1392 Thr Ser Val Ala Leu Ser Cys Gly Ser Asp Gly Asp Cys Gly Leu Val 120 1393 1394 Ala Val Ser Ala Gly Glu Val Phe Thr Glu Ser Arg Gln Gly Gly Ala 130 135 1396 Val Cys Ala Ser Ala Glu Asp Gly Phe Ala Val Ala Val Leu Gln 150 155 1398 Arg Asp Arg Ala Arg Gln Gly Val Val Ala Ser Leu Gln Ala Ser Val 170 1400 Ala Gln Arg Lys Trp Ala Arg Ala Ile Thr Gly Ala Val Ala Val Arg 185 180 1402 Val Ala Ser Leu Ala Thr Lys Ser Gly Ser Ser Gly Val Leu Leu Ser 195 200 1404 Ile Ala Val Ala Ile Val Val Gly Leu Asn Arg Leu Val Pro Met Cys 215 220 1406 Arg Gly Arg Ser Pro Leu Ile Glu Ser Ser Gly Val Glu Leu Ala Glu 230 1408 Ala Val Ser Pro Pro Pro Ala Ala Asp Gly Val Gly Ala Val Val Ile 245 250 1410 Ala Pro Glu Pro Glu Pro Leu Pro Glu Pro Gly Pro Val Gly Val Leu 260 265 1412 Ala Ala Ala Asn Ser Val Val Leu Leu Ala Arg Thr Glu Thr Ala Leu 280 285 1414 Ala Arg Leu Leu Glu Ser Ala Val Asp Asp Ser Val Pro Leu Thr Ala 290 300 1415 295 1416 Leu Ala Ser Ala Leu Thr Gly Ala His Leu Pro Arg Ala Leu Ile Ala 310 1418 Gly Asp His Glu Gln Leu Arg Gly Gln Arg Ala Val Glu Val Ala Ala 1419 330

PATENT APPLICATION: US/10/506,630

E: 04/21/2005 TIME: 09:58:27

Input Set : A:\30062-20046.01 - Seqlist (from parent .45).txt

Output Set: N:\CRF4\04212005\J506630.raw

1420 Pro Gly Ala Thr Thr Gly Thr Ala Ser Ala Gly Gly Val Val Phe Val 340 345 1422 Ala Glu Ala Arg Gly Ser Val Pro Glu Ser Ile Ala Glu Asp Ala Val 355 360 1423 •1424 Leu Ser Glu Val Ala Gly Phe Ser Ala Ser Glu Val Leu Glu Gln Arg 375 1426 Pro Asp Ala Pro Ser Leu Glu Asp Val Val Leu Ser Val Met Val Arg 390 395 🕔 1428 Leu Gly Ala Cys Val Ser Ser Ile Gln Ile Val Ala Val Leu Ser Leu 405. 410 1430 Glu Asp Gly Val Arg Val Val Ala Leu Arg Ala Lys Ala Leu Arg Ala 420 425 1432 Leu Ala Gly Arg Gly Gly Val Ser Leu Ala Ala Pro Gly Glu Arg Ala 435 440 1434 Arg Ala Leu Ile Ala Pro Trp Glu Asp Arg Ile Ser Val Ala Ser Ser 455 450 1436 Ser Val Val Val Ser Asp Pro Glu Ala Leu Ala Glu Leu Val Ala Arg 470 1437 465 475 1438 Cys Glu Asp Glu Gly Val Arg Ala Lys Thr Leu Pro Asp Tyr Ser Ser 490 1440 Arg His Val Glu Glu Ile Arg Glu Thr Ile Leu Ala Asp Leu Asp Gly 500 505 1442 Ile Ser Ala Arg Arg Ala Ala Ile Pro Leu Tyr Thr Leu His Gly Glu 520 1444 Arg Arg Asp Gly Ala Asp Met Gly Pro Arg Tyr Asp Asn Leu Ser Gln 530 535 540 1446 Arg Asp Glu Val Ser Ala Ala Val Ala Asp His Ala Thr Val Met Pro 550 555 1448 Val Ile Thr Ala Ala Val Gln Glu Ile Ala Ala Asp Ala Val Ala Ile 565 570 1450 Gly Ser His Asp Thr Ala Glu Glu His Ile Ile Ala Glu Leu Ala Arq 580 585 1452 His Val His Ala Val Asp Trp Arg Asx Val Phe Pro Ala Ala Pro Pro 595 600 1454 Val Ala Asn Glu Pro Gln Tyr Leu Ala Pro Glu Val Ser Gln Leu Ala 610 615 1456 Asp Ser Arg Arg Val Asp Arg Pro Leu Ala Thr Thr Pro Val Asp Leu 1458 Glu Gly Gly Phe Val His Gly Ser Ala Pro Glu Ser Leu Thr Ser Ala 1459 645 650 1460 Val Glu Lys Ala Gly Arg Val Val Pro Val Ala Ser Ala Asp Arg Glu 665 1462 Ala Ser Ala Ala Leu Arg Glu Val Pro Gly Glu Val Ala Gly Leu Val 675 680 1464 His Thr Gly Ala Ala Thr His Leu Ala His Gln Ser Leu Gly Glu Ala 690 695 700 1466 Gly Val Arg Ala Pro Leu Trp Leu Val Ser Arg Ala Leu Gly Glu Ser 710 1468 Glu Pro Val Asp Pro Glu Gln Ala Met Val Trp Leu Gly Arg Val Met

RAW SCHOOL LISTING
PATENT APPLICATION: US/10/506,630

E: 04/21/2005 TIME: 09:58:27

Input Set : A:\30062-20046.01 - Seqlist (from parent .45).txt
Output Set: N:\CRF4\04212005\J506630.raw

1469					725					730					735	
1470	Gly	Leu	Thr	Pro	Glu	Arg	Trp	Gly	Gly	Leu	Val	Leu	Pro	Ala	Glu	Pro
1471				740					745					750		
1472	Ala	Pro	Glv	Asp	Glv	Glu	Ala	Phe	Val	Cvs	Leu	Glv	Ala	Asp	Glv	His
•1473			755		1			760		- 1		1	765		1	
1474	Glu	Acn		Val	710	Aen	Hic		λνα	Туг	Gl ₃₇	λνα		17 a 7	Δτα	Λla
	Giu	770	GIII	Vai	110	ASP	775.		Arg	IYI	GIY	780	Deu	vai	Arg	AIG
1475	D		a3	mb	N	a 1			m	a 1			17-7	a 1	ml	61
1476		Leu	GIY	Int	Arg		ser	ser	Trp	GIU		Ата	vaı	GIA	inr	_
1477		_		•		790	•	_ ~	_	_	795		_	-		800
1478	Ala	Leu	GIY	His		Ala	His	Ala	Arg		Val	GIu	Asp	Val		Ser
1479			_	_	805	_		_	_	810		_	_	_	815	
1480	Arg	Arg	Gly		Asp	Ala	Pro	Gly		Ala	Glu	Glu	Ala			Val
1481				820					825		•			830		
1482	Ala	Ile	Ala	Lys	Thr	Thr	Ile	Thr	Cys	Val	Ala	Asp	Arg	Glu	Gln	Leu
1483			835					840				•	845			
1484	Ser	Lys	Leu	Leu	Glu	Glu	Leu	Arg	Gly	Gln	Gly	Arg	Pro	Val	Arg	Thr
1485		850					855					860				•
1486	Val	Val	Thr	Ala	Gly	Val	Pro	Glu	Ser	Arg	Pro	Leu	His	Glu	Ile	Gly
1487						870					875					880
1488	Glu	Leu	Glu	Ser	Val	Cys	Ala	Ala	Val	Thr	Gly	Ala	Arg	Leu	Asp	Leu
1489					885	-				890	-		_		895	
1490	Cys	Pro	Asp	Ala	Glu	Thr	His	Val	Leu	Phe	Gly	Gly	Val	Trp	Gly	Ser
1491	•		•	900					905	•	•	•		910	•	
1492	Ala	Asn	Leu	Glv	Ala	Ser	Ala	Ala	Asn	Ala	Tvr	Asp	Ala	Leu	His	Arq
1493			915	•				920			-	-	925			
1494	Ara	Ala	Glu	Ara	Ala	Ala	Thr	Ser	Val	Ala	Glv	Ala	Glv	Glu	Glv	Met
1495		930					935					940	4		- 4	
1496	Ala		Glv	Asp	Leu	Glu		Leu.	Thr	Ara	Ara	Leu	Ara	Pro	Met	Ala
1497			4			950	2			5	955		3			960
1498		Glu	Ara	Tle	Ara		Len	His	Gln	Ala		Asn	Glv	Asp	Thr	
1499		024			965					970	1.05	11011	U -1	1100	975	O _I L
1500	Val	Ser	Tle	Δla		Val	Asn	Trn	Glu		Phe	Δla	Val	Glv		Thr
1501				980	1.0p				985				·uı	990		
1502	Δla	Ara	Pro	-	Pro	Len	T.e.u	Asn		Len	Val	Thr	Pro		Val	Glv
1503			995	••••		Deu	200	1000		<u> </u>	·uı		1009		• • • •	O.J
1504	λla	t/a l		λla	t/a l	Gln	בומ			λκα	Glu	Mat			Gln	Glu
1505	AIG	1010		AIQ.	Val	GIII	1015		ΑΙα	Arg	Giu	1020		Der	GIII	Giu
1506	T 011			Th~	uic	Cor			77-	т1.	T 011			Cor	Dro	N an
1507			Pne	TIIL	птъ			vai	Ala	TIE			ser	ser		_
1507	77-) 170 1	۵1	71 -	7	1030) D	mb	α1	Dl	1035	m1	77-7	a1	7	1040
	Ala	vai	GIÀ	GIII			PIO	mr	GIU			THE	vai	GIA		
1509	_	~3	~7		1045			_	_	1050		_	-		1055	
1510	Leu	GIn	Gin			Leu	Ala	Leu			Thr	Leu	Val			Thr
1511	_			1060		_	_		1069				_	1070		
1512	Val	Arg			Asp	His	Ile			Gln	Asp	Ser	_		Pro	Ala
1513			1075					1080					1085	5		
1514	Arg	Glu	Ala	Ser	Ser	Ala			Asp	Gly	Tyr		•			
1515		1090)				1095	5 .								
· 1549(25)	Λ	Λα													
`		do.	lete	ر												
	•															

VERIFICION SUMMARY
PATENT APPLICATION: US/10/506,630

E: 04/21/2005 TIME: 09:58:28

Input Set : A:\30062-20046.01 - Seqlist (from parent .45).txt

Output Set: N:\CRF4\04212005\J506630.raw

L:16 M:271 C: Current Filing Date differs, Replaced Current Filing Date

L:65 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:3

M:332 Repeated in SeqNo=3

L:248 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:18 L:1549 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:41